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ABSTRACT
Extracellular vesicles (EVs) provide a complex means of intercellular signalling between cells at local
and distant sites, both within and between different organs. According to their cell-type specific
signatures, EVs can function as a novel class of biomarkers for a variety of diseases, and can be used as
drug-delivery vehicles. Furthermore, EVs from certain cell types exert beneficial effects in regenerative
medicine and for immune modulation. Several techniques are available to harvest EVs from various
body fluids or cell culture supernatants. Classically, differential centrifugation, density gradient
centrifugation, size-exclusion chromatography and immunocapturing-based methods are used to
harvest EVs from EV-containing liquids. Owing to limitations in the scalability of any of thesemethods,
we designed and optimised a polyethylene glycol (PEG)-based precipitation method to enrich EVs
from cell culture supernatants. We demonstrate the reproducibility and scalability of this method and
compared its efficacy with more classical EV-harvesting methods. We show that washing of the PEG
pellet and the re-precipitation by ultracentrifugation remove a huge proportion of PEG co-precipi-
tated molecules such as bovine serum albumine (BSA). However, supported by the results of the size
exclusion chromatography, which revealed a higher purity in terms of particles per milligram protein
of the obtained EV samples, PEG-prepared EV samples most likely still contain a certain percentage of
other non-EV associated molecules. Since PEG-enriched EVs revealed the same therapeutic activity in
an ischemic stroke model than corresponding cells, it is unlikely that such co-purified molecules
negatively affect the functional properties of obtained EV samples. In summary, maybe not being the
purificationmethod of choice if molecular profiling of pure EV samples is intended, the optimised PEG
protocol is a scalable and reproducible method, which can easily be adopted by laboratories
equipped with an ultracentrifuge to enrich for functional active EVs.
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In recent years, extracellular vesicles (EVs) such as
exosomes (Ø 70–150 nm) and microvesicles (Ø
100–1,000 nm) have been shown to be significantly
contributing towards intercellular signalling path-
ways under both physiological and pathophysiologi-
cal conditions [1,2]. EVs can be considered
extracellular organelles, which are assembled in a
cell-specific manner and can carry a variety of
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different biologically active molecules. These include
proteins involved in cell adhesion (e.g. intercellular
adhesion molecules [ICAMs] and integrins), intercel-
lular cell signalling (e.g. cytokines, interleukins and
chemokines) and membrane organisation (e.g. tetra-
spanins and flotillins) as well as coding and non-
coding RNAs (including microRNAs), and different
types of lipids [1,3–5]. The molecular organisation of
their surface provides a kind of address code allow-
ing them to selectively interact with specific target
cells [6,7]. Thus, depending on their origin and their
cargo, EVs can exert specific functions. For instance,
B-cell derived EVs expressing Major
Histocompatibility Complex (MHC)-class II mole-
cules are able to induce specific T-cell responses
(Raposo et al. 1996). Also, EVs derived from other
immune cell-types have been demonstrated to pro-
mote pro-inflammatory responses [8]; for example,
EVs from mature dendritic cells (DCs) that had been
pulsed with tumour-specific antigens can induce
antitumour responses in mouse and man [9–12].
In contrast, EVs deriving from tumour cells or
from somatic stem cells, especially from mesenchy-
mal stem/stromal cells (MSCs), regularly exert
immune suppressive rather than immune stimulating
functions [13–15]. Potentially related to their
immune suppressive effects, MSC-derived EVs
(MSC-EVs) exert beneficial therapeutic effects in ani-
mal models for different diseases, including acute
kidney failure, myocardial infarction, ischemic stroke
and asthma [16–21]. Furthermore, MSC-EVs have
been successfully used to treat a steroid-resistant
Graft-versus-host disease (GvHD) patient without
inducing any side effects [14]. In addition to their
therapeutic potential, EVs are increasingly recognised
as biomarkers for a variety of different diseases such
as cancer [22–24], and are considered drug-delivery
vehicles for different substances [20,25,26].
Although the EV field has significantly progressed
within the last few years, there is no consensus on
optimal isolation and purification methods.
Differential (ultra)centrifugation remains the stan-
dard technique to harvest EVs from tissue culture
supernatants as well as from primary body fluids
[27–29]. In addition, amongst others immunopreci-
pitation techniques [30], ultrafiltration [31] and size-
exclusion chromatography [32] are used to enrich for
EVs. Recently, increasing numbers of commercially
available polymeric precipitation reagents allow for
the precipitation of nanosized EVs at low speed
centrifugation. However, all of these techniques are
more suitable for preparations of small rather than
large sample volumes. For example, the largest rotors
for ultracentrifugation can process less than 400 mL
sample volume in one run. Thus, larger-scale pre-
paration approaches are required. Aiming to prepare
exosome-sized EVs (sEVs; 70–150 nm) for therapeu-
tic applications we searched for a novel, cost-effec-
tive method that allows harvesting of sEVs from
larger sample volumes (up to several litres).
In terms of size and molecular content, EVs and
viruses share a number of common features and use
parts of the same endosomal machinery for their
assembly and release [33]. Owing to these parallels,
a discussion had been initiated as to whether some
viruses, especially retroviruses, can be considered as
malignant exosomes [34]. Independent from the evo-
lutionary relation viruses and EVs indeed share, this
discussion led us to the assumption that technologies
allowing purification of viruses may provide feasible
technologies to purify sEVs as well. Since it is a well-
established procedure to concentrate viruses via
polyethylene glycol (PEG) precipitation [35–37], we
tested for the efficacy of PEG precipitation to con-
centrate sEVs from cell culture supernatants in both
small and large scales. PEG precipitation is affected
by the molecular weight of the PEG [38]; thus, we at
first compared the efficacy of PEG to precipitate
sEVs in relation to these parameters. After selecting
suitable conditions, we compared the yield obtained
with the small-scale PEG precipitation to that
obtained with other methods. Finally, we assessed
the reproducibility and the scalability of the estab-
lished PEG protocol and as a proof of principle
investigated the usability of prepared sEVs in down-
stream applications, i.e. miRNA profiling and pro-
teomic analysis.
Material and methods
Generation of CD63-eGFP transduced HEK293T
cells
The coding region of the tetraspanin CD63 was
amplified via polymerase chain reaction (PCR)
using HEK293T cell cDNA as tem
plate. The oligonucleotides used for the PCR reac-
tion were flanked by XhoI or EcoRI restriction site
sequences, respectively (5ʹ ACCGATCTCGAGCA
ATGGCGGTGGAAGGAGGAATG; 3ʹ ACCGA
TGAATTCTCACCTCGTAGCCACTTCTGATACT).
Of note, the 3ʹ-primer was designed without the
stop codon of the CD63 gene. XhoI/EcoRI digested
PCR products were transferred into the XhoI/EcoRI
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site of the transient expression vector pEGFP-N1
(Takara Bio Europe/SAS, Saint-Germain-en-Laye,
France). The obtained expression cassette was con-
firmed by Sanger sequencing. To test for the appro-
priate subcellular distribution of the encoded
CD63-eGFP-CD63 fusion protein, the obtained
pEGFP-N1-CD63 plasmid and the original
pEGFP1 plasmid were transfected into HEK293T
cells using Jetpei (Polyplus, Illkirch Cedex, France)
transfection reagent according to the manufac-
turer’s recommendations.
Next, the CD63-EGFP ORF was transferred as NheI/
BsrGI restriction fragment from the pEGFP-N1-CD63
plasmid into the lentiviral vector pCL6IEGwo contain-
ing the coding region of eGFP (kindly provided by
Helmut Hanenberg, University Hospital Essen). The
expression cassette of the resulting pCL6-CD63-eGFP
lentiviral plasmid was confirmed by Sanger sequencing.
Lentiviral particle containing supernatants were
obtained following simultaneous co-transfection of
HEK293T cells applying the Jetpei transfection reagent
together with the lentiviral plasmid pCL6-CD63-eGFP,
the helper plasmid pCD/NL-BH [39] and the codon-
optimised, human foamy virus envelope encoding plas-
mid pcoPE01 [40]. The gene expression from the
human cytomegalovirus immediate-early gene enhan-
cer/promoter was induced with 10 mM sodium buty-
rate (Merck, Darmstadt, Germany) 24 h post
transfection. Supernatants containing lentiviral parti-
cles were collected 48 h after transfection. Following
filtration through 0.45 µm filters (Sartorius, Göttingen,
Germany) and concentration by centrifugation at
25,000 × g for 90 min at 4°C in an Avanti J-26 XP
centrifuge using a JA 25.50 rotor (Beckman Coulter,
Krefeld, Germany) pellets of lentiviral particles were
resolved in 2.5 mL Iscove’s Modified Dulbecco’s
Medium (IMDM) . Aliquots of 250 µL were stored at
−80°C.
HEK293T cells raised in Dulbecco Modified Eagle
Medium (DMEM) high glucose supplemented with
10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin
and 100 U/mL glutamine (all Life Technologies,
Darmstadt, Germany) were transduced by overnight
exposure to virus stocks. Successfully transduced cells
were purified via fluorescent cell sorting on a fluores-
cence-activated cell sorting (FACS) Aria I cell sorter
(BD Bioscience, Heidelberg, Germany).
Culturing of HEK293T cells and collection of media
for the EV preparation
HEK293T-CD63-eGFP cells were cultured with
DMEM high glucose supplemented with 10% FBS,
100 U/mL penicillin, 100 U/mL streptomycin and
100 U/mL glutamine (Life Technologies). As soon
as the mycoplasma-free cells reached approximately
50% confluency, media for the EV purification were
collected each other day until the cells reached
80–90% confluency. Media were centrifuged at
2,000 × g. Supernatants were either used immediately
or filtered through a 0.22 µm filter (Sartorius,
Göttingen, Germany) and stored at −20°C until
usage. After thawing, aliquots were pooled to
500 mL batches. All cells were tested weekly for
mycoplasma contamination.
EV uptake experiments
Cells of the immortalised mesenchymal stromal cell
line N-KM (normal bone marrow) [41] were cul-
tured in 6- or 24-well plates in 10% FBS, 100 U/mL
penicillin, 100 U/mL streptomycin and 100 U/mL
glutamine (Life Technologies) supplemented IMDM
(Lonza, Cologne, Germany) until they reached
approximately 70% confluency.
For the analyses of EV uptake equivalents of
1 × 108 particles of the EV-enriched samples were
added to the cells. After incubation for 14–16 h at
37°C, the medium with residual particles was
removed and fresh culture media were added. At
first, cells were analysed by fluorescent microscopy
on an Axio Observer.D1 microscope platform with
Plan-Apochromat 20×/0.8 lenses (Zeiss, Oberkochen,
Germany). To harvest cells for flow cytometric ana-
lysis, cells were treated with 0.25% trypsin (Lonza)
for 5 min at 37°C. The enzymatic reaction was
stopped by the addition of fresh culture media.
Cells were pelleted by centrifugation for 5 min at
800 × g, re-suspended in isotonic solution for flow
cytometry (Beckman Coulter) and analysed on a
Cytomics FC500 flow cytometer (Beckman Coulter)
for their eGFP-intensity. The mean fluorescence
intensity was measured for all samples in comparison
to untreated N-KM cells.
EV preparation from conditioned cell media
Preparation by direct ultracentrifugation
10 mL of freshly harvested conditioned media were
centrifuged at 110,000 × g for 2 h at 4°C in an
Optima L7-65 ultracentrifuge using a SW40 swing-
out rotor (k factor 299, Beckman Coulter). Obtained
pellets were re-suspended in 1 mL phosphate-buf-
fered saline (PBS; Life Technologies). Obtained EVs
were either processed immediately, kept on −20°C
for short-term or −80°C for long-term storage.
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Preparation by differential centrifugation
10 mL conditioned media (freshly harvested or fro-
zen and thawed) were centrifuged at 10,000 × g for
45 min in a 5810R centrifuge (Eppendorf, Hamburg,
Germany). Supernatants were transferred to 10 mL
Ultra-Clear centrifuge tubes (Beckman Coulter), and
EVs were precipitated at 110,000 × g for 2 h at 4°C
in an Optima L7-65 ultracentrifuge using a SW40
swing out rotor (k-factor 299, Beckman Coulter).
For the comparison of the different methods,
obtained pellets were re-suspended in 1 mL PBS,
for the comparison of the reproducibility in 250 µL
0.9% sodium chloride (NaCl) (Braun, Melsungen,
Germany). Fractions were washed with 11 mL PBS
or 10 mL 0.9% NaCl, respectively, and re-precipi-
tated by ultracentrifugation exactly as previously per-
formed. Obtained EVs were either processed
immediately, kept on −20°C for short-term or −80°
C for long-term storage.
Preparation with PEG
Small-scale preparation. 10 mL conditioned media
(freshly harvested or frozen and thawed) were centrifuged
at 10,000 × g in a 5810R centrifuge (Eppendorf). Obtained
supernatants were supplemented with 50% w/v stock solu-
tions of PEG 6000, 8000 or 20000 (Sigma-Aldrich,
Taufkirchen, Germany) to final concentrations of 6, 8,
10, 12 and 15% PEG and with 3.75 M NaCl (Sigma-
Aldrich) to final concentration of 75 mMNaCl (calculated
to 15 mL). Samples were mixed gently by inverting the
tubes three times. Unless indicated otherwise, samples
were stored at 4°C for up to 14 h (overnight). EVs were
concentrated by centrifugation at 1,500 × g for 30min at 4°
C in a 5810R centrifuge (Eppendorf, Hamburg, Germany).
Supernatants were removed and pellets re-suspended in
250 µL PBS for initial experiments and 1 mL PBS for the
comparison of different methods or 250 µL 0.9% NaCl by
pipetting, respectively. To remove residues of PEG from
the suspension, the EV-enriched fractions were washed
with 11 mL PBS or 10 mL 0.9% NaCl, respectively, and
centrifuged at 110,000 × g for 2 h at 4°C in an Optima L7-
65 ultracentrifuge using the swing out rotor SW40 (k factor
299, Beckman Coulter). The resulting pellet was re-sus-
pended in 250 µL/1 mL PBS or 250 µL 0.9% NaCl, respec-
tively. Obtained EV samples were kept on −20°C for short
or −80°C for long-term storage.
Large-scale preparation. After freezing and thawing
360 mL conditioned media were centrifuged at
6,000 × g in 500 mL conical centrifuge flasks
(Beckman Coulter) in an Avanti J-26 XP centrifuge
using the swing-out rotor JS-5.3 (Beckman Coulter).
Obtained supernatants were transferred into new
500 mL conical centrifuge flasks and supplemented
to a final concentration of 10% PEG 6000 and
75 mM NaCl. After overnight incubation at 4°C,
EVs were precipitated at 1,500 × g in an Avanti
J-26 XP centrifuge using the swing-out rotor JS-5.3
(Beckman Coulter) for 30 min at 4°C. Pellets were
re-suspended in 60 mL 0.9% NaCl and transferred
in 70 mL polycarbonate centrifuge bottles (Beckman
Coulter). Fractions were precipitated at 110,000 × g
for 2 h at 4°C in an Optima L7-65 ultracentrifuge
using the tight angle rotor Ti45 (k factor 244,
Beckman Coulter). Obtained pellets were re-sus-
pended in 1 mL 0.9% NaCl and stored at −80°C
until usage.
Preparation with sucrose density gradient
EVs from 10 mL conditioned media were at first
prepared by differential centrifugation exactly as
described earlier. The obtained fractions (each
1 mL) were loaded onto an 11 mL sucrose density
gradient (2.5, 5, 10, 20, 30, 40, 50, 60, 70 and 75%)
and centrifuged at 110,000 × g for 16 h at 4°C in a
SW45 swing-out rotor in an Optima L7-65 ultracen-
trifuge (k factor 244, Beckman Coulter). Fractions of
1 mL each were taken from the top to the bottom.
After transferring 2 µL onto microscopic slides,
drops were checked for the presence of eGFP-
labelled particles by fluorescence microscopy using
the Axio Observer.D1 platform (Zeiss). Fractions
containing fluorescent particles were pooled and
diluted with PBS to 12 mL total volume and centri-
fuged at 110,000 × g for 2 h at 4°C in an Optima L7-
65 ultracentrifuge using the swing out rotor SW40 (k
factor 299, Beckman Coulter). Resulting pellets were
re-suspended in 250 µL PBS and used for EV uptake
experiments and Nano particle Tracking
Analysis (NTA).
Preparation by size-exclusion chromatography
EVs from 10 mL conditioned media were at first
prepared by differential centrifugation exactly as
described earlier. The obtained fractions (each
1 mL) were loaded onto columns of 16/60 HiLoad
Superdex 200 prep grade (GE Healthcare Europe
GmbH, Freiburg, Germany), which were pre-equili-
brated with a buffer containing 0.05 M sodium
phosphate (pH 7.2) and 0.15 M NaCl using an
ÄKTAexplorer 10 (GE Healthcare Europe GmbH,
Freiburg, Germany). Fractions of 1 mL were
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collected at a flow rate of 1 mL/min. The first six
elution fractions corresponding to the known reten-
tion volume for EVs were pooled and concentrated
to 1 mL by ultracentrifugation.
Analysis of obtained EV samples
Fluorescence drop analysis
1–2 µL of the obtained HEK293T-CD63-eGFP samples
were transferred to microscopic slides and analysed by
an Axio Observer.D1 fluorescent microscope with a
Plan-Apochromat 20×/0.8 objective (Zeiss).
Protein content
The protein content of the EV samples was determined
using the bicinchoninic acid BCA protein assay kit
(Pierce, Rockford, IL, USA). Protein analysis was per-
formed according to the recommendations of the man-
ufacturer using the 96-well plate procedure.
Western blot
Samples were solubilised with Laemmli sample buffer
containing DTT (AppliChem, Darmstadt, Germany)
and separated on an 1D sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) gel
before transfer to polyvinylidene fluoride membrane
(PVDF; Millipore, Darmstadt, Germany). Page Ruler,
Prestained Protein ladder (Thermo Fisher, 26616)
was used as a marker. PVDF membranes were
blocked in PBS-0.1% Tween-20 (PBS-T) or TBS-
0.1% Tween-20 (TBS-T) containing 5% (w/v) skim
milk powder (Sigma-Aldrich). To rinse off residual
blocking solution membranes were washed three
times (5, 10 and 20 min) in PBS-T/TBS-T. For the
detection of defined proteins, the following primary
antibodies (diluted either in PBS-T or TBS-T) were
used (clone, dilution, incubation time and tempera-
ture, company, article number): mouse anti-human
CD9 (VJ1, 1:1000, 4°C overnight, kindly provided by
Francisco Sánchez-Madrid), mouse anti-human
CD63, (TEA3, 1:1,000, 4°C overnight, kindly pro-
vided by Francisco Sánchez-Madrid), mouse anti-
human CD81 (JS-81, 1:1,000, 4°C overnight, BD
Bioscience, 555675), polyclonal rabbit anti-human/
mouse/rat HSP70/HSPA1A (1:1,000, 4°C overnight,
R&D Systems, Abingdon, United Kingdom, AF1663),
rabbit anti-human/mouse/rat Tsg101 (polyclonal,
1:1,000, 4°C overnight, Sigma-Aldrich, T5701), rabbit
anti-Syntenin (EPR8102, 1:1,000, 4°C overnight,
Abcam, Cambridge, United Kingdom, ab133267),
mouse anti-Prohibitin (II-14-10, 1:250, 4°C over-
night, Thermo Fischer, MA5-12858) and rabbit
anti-bovine serum albumin-HRP, (polyclonal
1:20,000, 2 h room temperature, Abcam ab7637).
To rinse off residual primary antibodies membranes
were washed three times (5, 10 and 20 min) in PBS-
T/TBS-T.
The following secondary antibodies and detection sub-
strates were used: Peroxidase-AffiniPure F(ab’)2 Fragment
Donkey Anti-Mouse IgG (polyclonal, 1:10,000, 1 h room
temperature, Jackson ImmunoResearch Laboratories,
West Grove, PA, USA, 715-036-150); Peroxidase-
AffiniPure F(ab’)2 Fragment Donkey Anti-Rabbit IgG
(polyclonal, 1:10,000, 1 h [for Tsg101 2 h] room tempera-
ture, Jackson ImmunoResearch Laboratories, 711-036-152;
Substrate: SuperSignal® West Femto Maximum Sensitivity
Substrate, Thermo Fisher, 34095.
Sample buffer conditions for gel run: non-reducing
(denatured but without DTT) for detection of CD9,
CD63, CD81; reducing for detection of HSP70,
Tsg101, Syntenin, Prohibitin; detection of BSA works
with both conditions.
Nanoparticle tracking analysis (NTA)
Average size distribution and particle concentration
analyses of the EV samples were performed by
NTA. At the beginning of the studies, a Nanosight
LM10 instrument equipped with the NTA 2.0 ana-
lytical software was used, exactly as described pre-
viously [42]. Each sample was measured three times.
The 50% median value (D50) and the standard
deviation were calculated. For comparison of the
differential centrifugation and the PEG 6000 preci-
pitation procedures, both, small and large scales,
NTA was performed on the ZetaView platform
(Particle Metrix, Meerbusch, Germany). The follow-
ing dilutions and settings were used:
Electron microscopy
Drops of 4 µL of selected EV samples were loaded on
formvar or carbon coated 300 mesh copper grids
(Plano, Wetzlar, Germany) for 2 min. The grids
were washed in double distilled water and contrasted
with either 1% uranyl acetate (SPI Supplies, West
Chester, USA) or 0.75% uranyl formate (SPI
Supplies) for 1 min. Grids were air dried and exam-
ined either on a JEM1400 Plus electron microscope
(JEOL, Tokyo, Japan) equipped with a LaB6 cathode
at 120 kV using a TemCam-XF416® FastScan CCD
camera system (TVIPS, Gauting, Germany) for image
acquisition or an EM 902A (Zeiss, Oberkochen,
Germany) electron microscope at 80 kV with a
Morada slow scan CCD camera connected to a PC
running ITEM 5.2 capturing software (Olympus SIS,
Münster, Germany).
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PEG concentration
The PEG concentration of the samples was measured
by a barium-iodide approach, which was analysed by
the ODYSSEY CLx 096A infrared imaging system
(LI-COR, Bad Homburg, Germany). In detail,
2–12 µg of the EV samples were re-suspended in
SDS-sample puffer (Thermo Fisher), heated for
10 min to 75°C and fractioned together with a PEG
6000 concentration series on 4–12% Bis Tris
NuPAGE gels (Thermo Fisher) via SDS PAGE.
After electrophoresis for 40 min at 200 V in
MOPS-buffer (Thermo Fisher) gels were washed
twice with distilled water. To visualise the PEG,
gels were incubated for 10 min in freshly prepared
5% barium chloride (ROTH, Karlsruhe, Germany)
and developed with 0.1 M iodide solution (ROTH,
Karlsruhe, Germany) [43,44]. After the positive
detection of the PEG signals, the solution was
exchanged for distilled water. PEG signals were
quantified by with ODYSSEY® CLx 096A infrared
imaging system and Image studio software (LI-
COR, Bad Homburg, Germany).
miRNA analysis
Total RNA (including miRNA-fraction) was
extracted from volumes of 400 µL of conditioned
cell culture medium or from EV samples either
obtained by the direct ultracentrifugation, differential
centrifugation or the PEG method utilising the
mirVana PARISTM kit (Ambion, Austin, USA). All
steps were performed according to the manufac-
turer’s instructions.
Relative miRNA-quantification was performed
using the miScript system (Qiagen, Hilden,
Germany) according to the manufacturer’s instruc-
tions. All samples, including non-RT (without
reverse transcriptase) and no-template controls were
assayed in duplicates. Mean Ct values and deviations
between the duplicates were calculated. Samples with
a deviation >0.5 within the duplicates or with any
evidence for melting curve abnormality were
repeated. Spike-in normalisation with synthetic C.
elegans derived cel-miR-54 sequence was performed
to allow relative comparison across the analysed
samples [45]. A normalised Ct value (Ctnorm) for
let-7 or miR-16, was determined relatively to the
syn-cel-miR-54 signal (Ctnorm = CtmiR-of-interest
– Ctsyn-cel-miR-54). Denoted relative abundance
values correspond to 2-Ctnorm.
Proteome analyses
Sample preparation for mass spectrometry of EV sam-
ples. For the in-gel digestion, 20 µg of EV samples
obtained by the large-scale PEG method were separated
by SDS PAGE. Staining was obtained by Imperial Stain
according to the manufacturer’s instructions (Thermo
Fisher). After electrophoresis gels were washed three
times for 5 min with distilled water and stained for 2 h.
Subsequently, each gel lane was cut in five equal pieces.
Destaining, alkylation, reduction, tryptic digestion and
peptide extraction was performed according to
Schrotter and colleagues [46].
FASP (filter-aided sample preparation) and in-solution
digestion. 10 µg of EV samples obtained with the
large-scale PEG method were diluted with 0.9% NaCl
to volumes of 50 µL. Subsequent steps, i.e. carbamido-
methylation, alkylation and tryptic digestion, were per-
formed exactly as described before [47,48].
Peptide mass spectrometry (MS). All samples for MS
measurements were purified via C18 tips as described
by the manufacturer (Thermo Fisher). Adjusting an
equal peptide concentration for all samples was
achieved by Nanodrop analysis (Peqlan, Erlangen,
Germany) and monolithic HPLC analysis (Agilent,
California, USA). LC-ESI MS/MS measurements were
performed on a LTQ Orbitrap Velosinstrument
(Thermo Fisher) combined with Dionex UltiMateTM
3000- Rapid Separation Liquid Chromatography
System (Thermo Scientific). For pre-concentration of
peptides a reversed-phase trapping column (Acclaim
PepMap RSLC 100 μm × 2 cm, 3 μm particle size,
100 Å pore size, Dionex) in 0.1% TFA was used. For
separation of peptides on a 75 μm RP column (RSLC
75 μm × 25 cm, 2 μm particle size, 100 Å pore size) and
Parameter settings LM10 Parameter settings Zeta view
Dilution and Solvent 1:50, 1:100 or 1:1,000 in water Dilution and solvent 1:2, 1:10, 1:100 or 1:1,000 in 0.9% NaCl
Viscosity 0.91cP Viscosity n.d.
Temperature 24.1°C Temperature 25°C
Camera level gain 2.0 Sensitivity 85
Detection threshold Auto Detection threshold n.d.
Blur 5 × 5 Blur n.d.
Minimum track length 250 frames Minimum track length 10–60 cycles
Minimum expected particle size 30 nm Minimum expected particle size 30 nm
n.d.: not detectable.
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a gradient (A 0.1% Formic acid (FA) and B 0.1% FA
84% ACN) ranging from 5 to 50% of solution B at a
ﬂow rate of 300 nL/min in 90 min. MS survey scans
were acquired from 300 to 2,000 m/z at a resolution of
30,000 using the polysiloxane m/z 371.101236 as lock
mass [49].
Results
HEK293T-CD63-eGFP cells release eGFP-labelled
EVs that can easily be detected by fluorescence
microscopy
To establish a scalable method to enrich sEVs from
tissue culture supernatants, we initially sought a quick
way to analyse the amount of precipitated EVs on a
qualitative level. To this end, we created expression
plasmids containing the coding region for CD63-
eGFP fusion proteins, either in a transient expression
plasmid (pEGFP-N1-CD63) or in a lentiviral vector
(pCL6-CD63-eGFP). Upon comparison of the subcel-
lular distribution of eGFP in HEK293T cells either
transfected with the pEGFP-N1-CD63 plasmid or the
empty pEGFP-N1 vector, a localised eGFP pattern was
observed at the plasma membrane and within the
endosomal compartment of HEK293T cells that were
successfully transfected with the pEGFP-N1-CD63-
eGFP plasmid. In contrast, successfully transfected
pEGFP-N1 HEK293T cells showed a uniform eGFP
distribution throughout the cells. To test for the pre-
sence of eGFP in EV-enriched fractions, supernatants
of transfected cells were harvested and processed by
direct ultracentrifugation. Drops of 1 to 2 µL of the
dissolved pellets were transferred onto slides and ana-
lysed by fluorescence microscopy. In contrast to the
drops of eGFP-transfected HEK293T cells, drops of
CD63-eGFP transfected cells showed a high concentra-
tion of eGFP+ particles especially enriched at the drop
edges, the contact zone of glass, air and liquid, that
could easily be seen at 200 × magnification (Figure 1).
Thus, we concluded that CD63-eGFP fusion proteins
but not eGFP itself are efficiently targeted into EVs
secreted by HEK293T cells. Subsequently, we trans-
duced HEK293T cells with CD63-eGFP encoding len-
tiviral particles and observed a subcellular eGFP
distribution comparable to the pEGFP-N1-CD63 trans-
fected HEK293T cells. Furthermore, the direct ultra-
centrifugation pellets of corresponding supernatants
were highly enriched in eGFP-labelled particles as
well. To obtain a permanent cell source for eGFP
labelled EVs, successfully transduced HEK293T-
CD63-eGFP cells, which were identified as cells with
high eGFP expression, were purified by fluorescent cell
sorting. Their conditioned media were used as EV
source for all experiments described below.
PEG precipitates EVs from conditioned cell culture
medium
Next, we evaluated whether PEG is an appropriate
reagent for the precipitation of CD63-eGFP labelled
sEVs from HEK293T-CD63-eGFP cell conditioned
media. For the initial setting, PEG 6000, PEG 8000
and PEG 20000 were used either at 6, 8, 10 and 12%
or 15% final PEG concentration. Together with NaCl
(75 mM final concentration) corresponding amounts
of 50% (w/v) PEG stock solutions were added to 10 mL
conditioned media that after harvesting as cell super-
natants had been filtered through 0.22 µm filters
before. Following incubation overnight at 4°C, the
samples were centrifuged for 30 min at 1,500 × g. To
remove residual PEG and reduce the amount of non-
vesicle-associated proteins that might had been co-pre-
cipitated, we washed the EV fractions in PBS and re-
precipitated them by ultracentrifugation. As a control,
EVs from the same volume were precipitated by direct
ultracentrifugation.
After confirming the presence of CD63-eGFP
labelled EVs by fluorescence microscopy, the particle
concentration and their size distribution were analysed
by NTA [42,50]. As depicted in Figure 2(a), analysis of
the particles harvested per mL conditioned media
(CM) revealed PEG concentration dependence for all
PEG variants. For PEG 6000, the highest particle yield
was obtained at a concentration of 10–12%, for PEG
8000 and PEG 20000 at 8–10% (Figure 2(a)). At these,
PEG concentrations the obtained particle numbers
were almost in the same range as in the pellets received
by ultracentrifugation (UC).
Independent of the molecular weight and the con-
centration of the PEG, the average sizes of the mea-
sured particles were in comparable ranges, on an
average diameter of 143 ± 20 nm (Figure 2(b)). In
terms of protein concentration within the recovered
fraction, the protein content increased with the PEG
concentration (Suppl. Table 1). The ratio of particles
per mg protein was calculated and considered as purity
index of the obtained EV samples (Figure 2(c)). All
PEG enriched EV samples were of higher purity than
those obtained by direct ultracentrifugation. On aver-
age, the highest purities were obtained with 12% PEG
6000, 8% PEG 8000 and 8% PEG 20000.
Since NTA cannot discriminate between vesicles and
other particles, western blots for the exosomal marker
protein Tsg101 were performed. To test for EV recovery
rather than for the purity, equal volumes of the obtained
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Figure 1. CD63-eGFP but not eGFP expressing HEK293T cells release high quantities of eGFP-labelled particles into their extra-
cellular environment. After processing of supernatants of HEK293T cells either transfected with eGFP-encoding plasmids (left side)
or CD63-eGFP-encoding plasmids (right side) with ultracentrifugation, 1 µL of each resolved pellet was transferred onto a
microscopic slide and allowed to dry (results in crystal formation). At the original border of the HEK293T CD63-eGFP drop, high
amounts of GFP+-particles were concentrated. Upper row: fluorescent image, lower row: overlay fluorescent and bright field images;
scale bar: 50 µm for all images.
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EV samples were loaded here (Figure 2(d)). In good
agreement with the results of the NTA, the samples
with the highest particle numbers were found to contain
the highest amount of Tsg101. To further test for the
presence of EVs within the obtained PEG samples, trans-
mission electron microscopy (TEM) images were taken.
Vesicle-like particles were found in all samples analysed
(data not shown). In summary, 10–12% PEG 6000,
Figure 2. Comparison of different PEG precipitation conditions. Conditioned media were diluted with PEG 6000 (P6), PEG 8000 (P8)
or PEG 20000 (P20) to final concentrations of 6, 8, 10, 12 or 15% (v/v), respectively. Following incubation overnight at 4°C, EVs were
precipitated by centrifugation at 1,500 × g for 30 min (4°C). EVs precipitated by direct ultracentrifugation (UC), served as control.
Obtained pellets were re-suspended in PBS and re-precipitated at 110,000 × g for 2 h (4°C). After dissolving in 250 µL PBS, the
particle concentration (n = 5; SD); (a) and their average size distribution (n = 5; SD); (b) were assessed by NTA (LM10). The purity of
the obtained samples was determined as particle numbers – measured by NTA – per µg protein content – measured by the BCA
assay (n = 5; SEM; (c). The presence of the exosomal marker protein Tsg101 was analysed by western blot; 20 µL of each fraction
were loaded per lane (d). Conditioned media were diluted with PEG 8000 to a final concentration of 10% PEG 8000 (v/v). Following
incubation for 1, 2, 4 and 8 h or overnight (16 h) at 4°C, respectively, EVs were precipitated by centrifugation at 1,500 × g for 30 min
(4°C). Obtained pellets were re-suspended in PBS and re-precipitated at 110,000 × g for 2 h (4°C). After dissolving in 250 µL PBS, the
particle concentration was measured by NTA (n = 3; SD) and the presence of the exosomal marker protein Tsg101 was analysed by
western blot; 5 µg protein of each Fraction was loaded per lane (e).
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8–10% PEG 8000 as well as 8–10% PEG 20000 appeared
appropriate to quantitatively precipitate sEVs. Since dis-
solved PEG 20000 has a higher viscosity and is more
difficult to handle without revealing any advantages
regarding recovery and purity, PEG 20000 was not con-
sidered in the following experiments.
The efficacy of PEG precipitation increases over
time reaching the maximum after 8 h
Following the initial experiments in which the sEVs
were precipitated overnight, we aimed to reduce the
preparation time and compared the EV-yield of 10 mL
of HEK293T-CD63-eGFP conditioned media upon
reducing the precipitation time to 1, 2, 4 or 8 h at 4°
C. Overnight precipitation served as control. As a
representative for the selected PEG precipitation con-
ditions, we chose the 10% PEG 8000 precipitation. We
observed green fluorescent particles under all condi-
tions. NTA and western blot analyses for Tsg101
showed increasing particle numbers and Tsg101 inten-
sity with increasing precipitation times. The maximum
recovery was observed in both analysis (NTA and
western blot) after 8 h (Figure 2(e)).
Comparison of different methods for EV
enrichment
In order to assess the efficacy of the PEG precipitation
method, we decided to prepare sEVs from HEK293T-
CD63-eGFP conditioned media with different EV pur-
ification technologies. We performed differential cen-
trifugation, with and without subsequent sucrose
gradient centrifugation or size exclusion chromatogra-
phy using a 1.5 × 45 cm Sepharose CL-2B column,
respectively. In relation to the differential centrifuga-
tion protocol, 10% PEG 6000 and 10% PEG 8000 pre-
cipitation were performed with supernatants that had
been centrifuged at 10,000 × g. Direct ultracentrifuga-
tion served as control.
All methods were accomplished with a starting
volume of 10 mL of freshly harvested conditioned
media of HEK293T-CD63 cells.
All obtained samples were analysed by NTA and
their protein content was determined. We noticed a
significant loss in particle numbers following sucrose-
density gradient and size exclusion chromatography
(Figure 3(a)); simultaneously, a slight reduction of the
average particle sizes was observed in these samples
(Figure 3(b)). In addition, their protein content was
very low. However, these preparations revealed the
highest particle content per protein amount, which
indicates a higher purity of these samples compared
with the EV samples that were obtained by PEG-pre-
cipitation, ultracentrifugation or differential centrifuga-
tion, respectively (Figure 3(c)). The yield we obtained
from 10 mL conditioned medium was not sufficient to
perform all analyses for each sample. In particular,
western blots and cellular uptake experiments were
not performed with the size exclusion samples and
only with reduced amounts of the sucrose gradient
samples.
The western blot analyses of 10 µg of the tested EV
preparation revealed similar intensities for Tsg101 in
the UC, DC and PEG samples. A stronger Tsg101
signal was obtained for the sucrose gradient fraction
(Figure 3(d)). Differences in the morphology of the
EVs prepared by the different methods have not been
identified (Figure 3(e)). Thus, as already suggested by
the particle to protein ratio, the sucrose gradient pre-
paration allowed for the highest sEV purification
amongst the methods tested here.
PEG does not recognisably affect the uptake of
enriched sEVs by their target cells
Aiming to establish a scalable method that can be used
for the purification of functional sEVs, it is important
that the purification method does not affect their bio-
logical properties. Considering that uptake by target
cells is an essential prerequisite that EVs can fulfil
their function, uptake experiments were performed.
To this end, HEK293T-CD63-eGFP sEVs prepared
with the different methods were added to cells of the
human mesenchymal stromal cell line N-KM. After
18 h, the cells were analysed via fluorescence micro-
scopy (Figure 3(f)) and flow cytometry (Figure 3(g)).
Both technological platforms demonstrated that PEG-
precipitated EVs were incorporated in virtually all
N-KM cells. The eGFP tagged protein was concen-
trated in the perinuclear region of the HEK293T-
CD63-eGFP EV treated N-KM cells (Figure 3(f)).
Flow cytometric data revealed comparable eGFP inten-
sities in N-KM cells that were incubated with EV
samples of the PEG precipitation or the differential
centrifugation. N-KM cells that had been incubated
with sEVs obtained from direct ultracentrifugation,
however, showed a more intense eGFP labelling
(Figure 3(g)). Most likely, this high intensity was
caused by non-incorporated eGFP-positive aggregates
that had been bound to the extracellular surface of
corresponding cells (Figure 3(f)). In contrast, N-KM
cells cultured in the presence of sucrose density gradi-
ent centrifugation purified HEK-293T-CD63-eGFP
EVs hardly showed any eGFP label (Figure 3(f,g)).
Since comparable amounts of eGFP+ particles were
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detected by fluorescence microscopy in sample drops
(data not shown), our findings suggest that sucrose
alters the EVs’ physiological features during the pre-
paration process. In contrast, PEG precipitation
appears as a reliable method to enrich for EVs without
affecting their uptake by selected target cells. Based on
our results, we concluded that size exclusion chroma-
tography and sucrose density centrifugation in the
applied form are not appropriate to prepare EVs in
larger amounts for subsequent functional studies.
The PEG-precipitation procedure is a reproducible
EV preparation method
So far, the PEG precipitation appeared to be a reliable
method to enrich sEVs from cell culture supernatants.
To finally qualify a robust PEG protocol, we slightly
changed the protocol. Since PEG 20000 is very viscous
and more difficult in handling than lower molecular
weight PEG variants, we considered that a lower mole-
cular weight of PEG facilitates its removal from given
sEV samples. Thus, without detecting significant differ-
ences between PEG 6000 and PEG 8000 precipitation,
we decided to continue with PEG 6000 only. To keep
the concentration as low as possible, we utilised 10%
instead of 12% final PEG concentration. To test for the
reproducibility of the PEG method, we used conditioned
media from four different, single cell-derived CD63-
eGFP HEK293T cell lines (clones C5, F5, E7 and B2).
Furthermore, we compared the PEG method to the
differential centrifugation method. To this end, 60 mL
of frozen and thawed conditioned media of each
HEK293T-CD63-eGFP cell clone were split into six
aliquots, 10 mL each. Three aliquots per clone were
processed according to the differential centrifugation
protocol. The other three samples per clone were
Figure 3. Comparison of different methods to enrich nano-sized EVs. EVs from 10 mL HEK293T-CD63-eGFP (single-cell clones C5, F5,
E7 and B2) cell conditioned media were either prepared by direct ultracentrifugation (UC), differential centrifugation (DC), PEG 6000
or PEG 8000 precipitation, density gradient centrifugation (DG), or size-exclusion chromatography (SE). The particle concentration
(n = 3; SD, (a) and their average size distribution (n = 3; SD, (b) were assessed by NTA (NanoSight LM10). The purity of the obtained
samples was determined as particle numbers – measured by NTA – per µg protein content – measured by the BCA assay (n = 3; SD,
(c). The presence of the exosomal marker protein Tsg101 was analysed by western blot; 10 µg of each fraction were loaded per lane
(d). Electron micrographs of samples from UC, DC, DG and PEG enriched EVs were acquired; scale bars 200 nm (e). To test for
potential impacts on the physiology of the obtained EVs, uptake experiments were performed: 1 × 108 particles as estimated by
NTA were supplemented to the media of N-KM cells. After 14–16 h, pictures were taken (f) before the amount of the eGFP labelling
was quantified as the mean fluorescence intensity (MFI) by flow cytometry (n = 3; SD, t-test,*p > 0.05, (g)). Scale bars 10 µm.
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processed according to the PEG protocol and re-sus-
pended in a final volume of 250 µL 0.9% NaCl. Of note,
calcium phosphate is purely soluble in water (2.07 ×
10−33 mol/L) and efficiently forms nano- to micro-
sized crystals (Ca5(PO4)3OH), which can be detected
by NTA [51] (Suppl. Figure 1). As biological samples
often contain Ca2+ ions, which may end up in prepared
EV samples, we decided to replace PBS and any other
phosphate-based buffer with clinical grade 0.9% NaCl as
solvent and washing solution for this and the following
experimental part.
All obtained samples were analysed by NTA to
calculate the total particle numbers and the average
size of harvested particles; in addition, total protein
content of all EV samples was determined, allowing
calculation of the EVs’ purity as particles per mg pro-
tein (Figure 4(a–c)). In terms of particle numbers,
higher yields and purities were obtained with the
PEG precipitation protocol than with the differential
centrifugation protocol (Figure 4(a,c)). Particle-sizes
and -amounts were comparable between each set of
the three samples of the conditioned media obtained
from the four different HEK293T-CD63-eGFP clones,
when the PEG method was used (Figure 4(a,b)). Except
for one EV-sample derived from the supernatant of
HEK293T-CD63-eGFP clone F5 cells, the purity within
the triplicates was comparable as well (Figure 4(c)). To
a larger extent, inter-experimental differences concern-
ing the particle numbers were observed in the samples
obtained by the differential centrifugation method
(Figure 4(a)). Thus, in our hands, the PEG method
provides higher particle yields and purities and is
more reproducible than the differential centrifugation
method.
Figure 4. PEG-precipitation versus differential centrifugation (DC). EVs from 10 mL HEK293T-CD63-eGFP cell conditioned media
were either prepared by PEG precipitation or differential centrifugation. The particle concentration per fraction (n = 3; SD, (a) and
their average size distribution (n = 3; SD, (b)) were assessed by NTA (ZetaView). The purity of the obtained samples was determined
as particle numbers – measured by NTA – per mg protein content – measured by the BCA assay (c). The presence of the EV marker
proteins HSP70, CD63, CD81 and CD9, and within the individual PEG samples was analysed by western blot; 5 µg proteins were
loaded per lane (d). The content of CD81, CD9 and BSA was compared in final EV samples harvested from of HEK293T-CD63-eGFP
clones C5, F5, E7, either harvested by PEG 6000 precipitation (PUP) or differential centrifugation (DCP). Proteins obtained from
supernatants of the final PEG pellets (PUS) or the ultracentrifugation pellet (DCS) obtained in the differential centrifugation method
served as controls. 2.5 µg proteins were loaded per lane (e). Of note, following analyses of CD81 blots were stripped and re-analysed
for the presence of BSA.
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To confirm the reproducibility of the PEG method at
the molecular level, western blot analyses with anti-
HSP70, anti-CD-63, anti-CD81 and anti-CD9 were per-
formed (Figure 4(d)). For all tested antigens, the signal
intensities of the bands were comparable in each of the
triplicates (Figure 4(d)). To test for contamination by
serum proteins and as HEK293T cells were cultured in
the presence of 10% FBS, we compared the BSA content
with that of CD81 and CD9 in representative samples.
To this end, one of the final PEG and one of the final
differential centrifugation samples of the HEK293T-
CD63-eGFP clones C5, F5, E7, either obtained by PEG
6000 precipitation or differential centrifugation, were
analysed. For comparison, proteins of corresponding
final supernatant samples of the PEG precipitation and
supernatant samples of the first ultracentrifugation step
of the differential centrifugation procedure were ana-
lysed as well. CD81 and CD9 were specifically detected
in all final samples analysed, but in none of the super-
natants (Figure 4(e)). A clear BSA signal was obtained in
the ultracentrifugation supernatant samples of the differ-
ential centrifugation method, and a very weak signal in
ultracentrifugation supernatants of the PEGmethod. In a
comparable manner, BSA signals were hardly detected in
the final PEG samples, but faint bands were recognised
in the final differential centrifugation samples
(Figure 4(e)).
Thus, the western blot data confirm a high reprodu-
cibility of the final PEG protocol. Furthermore, the
results demonstrate that PEG-precipitated sEVs are
less contaminated with BSA than sEVs prepared with
the differential centrifugation method.
The PEG-precipitation procedure is a scalable
method
To test for the scalability of the PEG method, 360 mL
conditioned media of each of the four different clonal
HEK293T-CD63-eGFP cell lines were processed with the
scaled PEG method in 500 mL conical centrifuge vials.
Owing to speed limitations of the vials and the JS-5.3
swing-out rotor, thawed conditioned media were centri-
fuged at 6,000 × g instead of 10,000 × g. PEG and NaCl
were added in a scaled manner. Final EV pellets were re-
suspended in 1mL 0.9%NaCl and used for all downstream
analyses.
The yield of particles per 1 mL conditioned medium
as measured by NTA was roughly in the same range of
magnitude for all four preparations than that of the
corresponding low-scale PEG preparations (Figures 4
(a) and 5(a)). The average size distribution and purity
were comparable as well (Figures 4(b,c) and 5(b,c)).
Thus, these data support the scalability of the PEG
method. Since we had enough material for downstream
analyses here, we comprehensively analysed the
obtained samples. Comparable to the low-scale PEG
samples, all final samples showed clear bands in wes-
tern blot analyses probed with anti-HSP70, anti-
Tsg101, anti-CD-63, anti-CD81 and anti-CD9 antibo-
dies, respectively. Additionally, clear bands were
obtained in western blots for Syntenin but not for
BSA, which was probed on the same blot than
Syntenin (Figure 5(d)). To test for the presence of
contaminating proteins, western blots for BSA and
the mitochondrial protein Prohibitin were performed.
Prohibitin and BSA were below the detection levels in
all final samples (Figure 5(d)).
To document enrichment of the EVs during the PEG
6000 precipitation procedure, western blot analyses for
CD81, CD9, HSP70 and Tsg101 were performed on
samples of the conditioned media from cells of all four
HEK293T-CD63-eGFP clones, on the supernatants and
the pellets of the 6,000 × g centrifugation step, the PEG
pellets and on the supernatants and the pellets of the
final ultracentrifugation procedure. CD81, CD9 and
Tsg101 were detected in all PEG pellets and in a more
enriched manner in the final samples (Suppl. Figure 2A).
Parts of the HSP70 were also found in the supernatant of
the ultracentrifugation pellet, resulting in comparable
HSP70 concentrations in PEG and ultracentrifugation
pellets (Suppl. Figure 2A). In a representative manner,
corresponding samples obtained from HEK293T-CD63-
eGFP clones E7 and B2 conditioned media were also
probed with anti-BSA antibodies. Here, an opposite
picture was obtained. BSA was detected in high amounts
in the conditioned media and the supernatants and
pellets of the 6,000 × g centrifugation step. Massively
reduced BSA levels were detected in the PEG pellet and
the supernatant of the final ultracentrifugation step but
not in the final EV fraction, which – on the same blot –
showed strong enrichment of CD81 (Suppl. Figure 2B).
The mitochondrial protein Prohibitin was used as a
representative marker to detect contaminations caused
by cell organelles. It was detected in cell lysates but not
in any of the conditioned media fractions (data not
shown).
Our analyses demonstrate that PEG 6000 preci-
pitation results in a specific enrichment of EV-asso-
ciated proteins. Furthermore, co-precipitated
contaminants within obtained PEG 6000 pellets,
such as BSA, can effectively be reduced from the
fraction of the PEG pellet by an additional ultra-
centrifugation step. Cellular organelle contamina-
tions were not detected. Thus, the large-scale PEG
precipitation appears to be a reliable method to
highly concentrate sEVs.
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To test whether enriched EVs can be taken up by
target cells, obtained EVs were added to N-KM cells as
described above. Fluorescence microscopy and flow
cytometric analyses confirmed incorporation of eGFP
into the N-KM cells (Figure 5(e)), implying that purified
CD63-eGFP labelled EVs still retain their properties to
be taken up by N-KM cells. Using the same protocol to
prepare sEVs from supernatants of MSCs, we demon-
strated that these MSC-EVs were able to exert therapeu-
tic effects in different animal models and in a human
GvHD patient [14,16,52,53]. Since these PEG-prepared
sEV samples exerted the same therapeutic effects in a
murine ischemic stroke model than corresponding MSCs
[16], our results demonstrate the usability of the PEG-
precipitation method as a scalable method for the enrich-
ment of biologically active sEVs.
PEG is efficiently depleted during the washing
procedure
In order to quantify the residual PEG concentration in
the final HEK293T-CD63-eGFP EV samples that might
interfere with down-stream applications, different
approaches were performed. Initially, a chloroform-
ammonium-iron thiocyanate-extraction method was
used to quantify pure PEG [54]. Although PEG could
be quantified in PEG-containing control samples, the
PEG concentration within the final HEK293T-CD63-
eGFP EV samples (clone B2 and C5 EVs were tested)
was below the optimal detection range of this method
(data not shown). Thus, a more sensitive barium-
iodide staining technique [43] was selected to analyse
HEK293T-CD63-eGFP EV samples.
Figure 5. Up-scaling of PEG-precipitation. EVs from 360 mL HEK293T-CD63-eGFP cell conditioned media were prepared by PEG
precipitation. The particle concentration per fraction (n = 3; SD, (a) and their average size distribution (n = 3; SD, (b) were assessed
by NTA (ZetaView). The purity of the obtained samples was determined as particle numbers – measured by NTA – per mg protein
content – measured by the BCA assay (c). The presence of the EV marker proteins HSP70, Tsg101, CD63, CD81 and CD9 within the
individual PEG samples was analysed by western blot. Additionally, the content of BSA, Syntenin and Prohibitin within the final
samples was compared; 5 µg proteins were loaded per lane (d). To test for potential impacts on the physiology of the obtained EVs,
uptake experiments were performed: 30–50 µg of the obtained samples were supplemented to the cell culture media of N-KM cells.
After 14–16 h pictures were taken, then, the amount of the eGFP labelling was quantified as the mean fluorescence intensity (MFI)
by flow cytometry (e). Scale bars 20 µm.
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For the quantification, different dilutions of pure PEG
were separated on a SDS gel in parallel to EVs harvested
from supernatants of HEK293T-CD63-eGFP clone B2
and C5 cells. Following the barium-iodide staining, the
PEG bands of the final EV samples showed similar
intensities than the bands of the 0.1% PEG dilutions.
The analyses of the PEG signals from the EV samples
and from the PEG dilution series revealed a PEG con-
centration of 0.02% in both final HEK293T-CD63-eGFP
EV samples tested (Figure 6(a,c)). To visualise proteins,
the gels were counterstained with the protein specific
imperial stain. In contrast to the PEG dilutions, EV
sample containing lanes were positively stained
(Figure 6(b)). Thus, only very low PEG levels were
detected in both final HEK293T-CD63-eGFP EV sam-
ples, demonstrating that the PEG used for the EV pre-
cipitation was efficiently washed out during the final
steps of the applied PEG precipitation procedure.
Following FASP protein PEG-samples can be
effectively analysed by proteomic profiling
Owing to the presence of some residual PEG in final
samples, its potential interference with proteomic
profiling was investigated in a proof of principle
experiment. In order to deplete residual PEG a SDS
PAGE of 20 µg of the final HEK293T-CD63-eGFP
clone C5 EV sample was run, including a proteolytic
in-gel digestion. Owing to the sensitivity of modern
MS/MS devices, PEG-originated signals were still
detectable (Suppl Figure 3A), which interfered with
the peptide counts of corresponding peptides result-
ing in a decrease of the sensitivity of the proteome
analysis. To eliminate the residual PEG, a FASP was
performed. After FASP, purified samples hardly con-
tained any PEG reminiscent that was detected in
subsequent MS/MS analyses (Suppl. Figure 3B).
Thus, in combination with the ultracentrifugation-
based washing procedure and the FASP, the applied
PEG procedure can be combined with proteomic
analyses.
PEG-precipitation does not interfere with the
enrichment and detection of vesicle-associated
microRNAs
To test whether residual PEG interferes with the enrich-
ment and quantitative assessment of EV-associated
microRNAs (miRNAs), a proof of principle miRNA ana-
lysis on a PEG-precipitated HEK293T-CD63-eGFP sEV
fraction was performed in comparison to corresponding
sEV samples obtained from differential centrifugation or
direct ultracentrifugation, respectively. To this end, the
abundance of the EV-associated miRNA let-7a and of the
Argonaute 2-associated miR-16, reported as being
excluded from EVs [45,55], was analysed.
Using the PCR-based StepOnePlusTM system, both
microRNAs were shown to be expressed in HEK293T-
CD63-eGFP cells. In RNA fractions extracted from
400 µL HEK293T-CD63-eGFP cell-conditioned medium,
a robust miR-16 level was confirmed in a proof of principle
experiment, whereas let-7a was hardly detectable. In con-
trast, the sEV samples prepared from volumes of 50 mL
HEK293T-CD63-eGFP cell-conditioned medium con-
tained increased levels of let-7a, but hardly any miR-16
(Suppl. Figure 4). Highest let-7a levels were found in the
sEV fraction prepared with the PEG method. Thus, the
PEG-precipitation apparently does not interfere with the
qualitative and quantitative assessment of EV-associated
microRNAs.
Discussion
To establish a cost-effective method allowing prepara-
tion of sEVs from larger sample volumes (up to several
litres) for functional studies, we have optimised a PEG
precipitation protocol. To efficiently concentrate sEVs,
we finally added PEG 6000 and NaCl to concentrations
of 10% PEG and 75 mM NaCl to conditioned cell
culture media. Following incubation for at least 8 h at
4°C, sEVs were precipitated at 1,500 × g. The presence
of contaminants was reduced by washing with 0.9%
NaCl and re-precipitation of the sEVs by ultracentrifu-
gation. Our results confirm the reproducibility and
scalability of the developed method. In proof of prin-
ciple experiments, we show that sEVs prepared with
the PEG method are effectively incorporated into target
cells. Furthermore, we have successfully used the opti-
mised PEG method to prepare sEV samples for the
preclinical and clinical setting from several litres of
MSC-conditioned media [14,16,52,53]. Upon compar-
ing the therapeutic impacts of such MSC-EV samples
with that of corresponding MSCs in a murine ischemic
stroke model, we did not detect any functional differ-
ence [16]. We also did not detect any impact on the
average particle size of sEVs. Thus, PEG which under
certain conditions can promote membrane fusion,
apparently does not interfere with the integrity of
EVs and allows preparation of functional sEVs from
cell culture supernatants.
As described, sEVs seem to exert most therapeutic
functions of MSCs [16,56]. However, in other cell
systems larger vesicles have been found to also mediate
functional activities [57]. Although we have not tested
this, larger EVs very likely can be co-enriched if the
10,000/6,000 × g centrifugation and the 0.22 µm
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filtration steps are dropped. In the presented experi-
ments, we used unprocessed FBS to raise the
HEK293T-CD63-eGFP cells. As FBS is known to
contain sEVs, non-metabolised FBS sEVs were very
likely included in the obtained sEV samples. It was
not our aim to remove them or estimate their content.
However, if prepared sEV samples should not contain
any medium derived-sEVs, the usage of EV-reduced/
depleted/free media is required to raise the cells. The
PEG method certainly will not allow to separate differ-
ent sEV types from each other.
In addition to functional studies, obtained sEVs
samples can be used for proteomic and miRNA ana-
lyses. Indeed, Andreu and colleagues compared several
commercial and non-commercial methods to enrich
EVs from frozen serum samples to subsequently extract
EV-associated miRNAs and obtained the best result
with our optimised PEG protocol [58]. In addition,
other groups have enriched EVs via PEG precipitation
and successfully used these EVs for proteomic analyses
[59,60]. Thus, we and others have demonstrated that in
addition to functional assays PEG precipitation is a
reliable method to enrich EVs for molecular down-
stream analyses. However, upon comparison of sEV
samples prepared with the optimised PEG protocol
with sEV samples prepared by size exclusion chroma-
tography or sucrose density gradient centrifugation, we
learned that higher purity indices can be obtained with
the later methods. Accordingly, we like to conclude
that despite their functional activities PEG-prepared
sEV samples contain several non-EV associated mole-
cules, which have not been identified, yet. Especially, if
sEVs are enriched from plasma samples or other pro-
tein rich body liquids, non-EV associated molecules
might by far be stronger concentrated than the sEVs,
questioning whether PEG precipitation should be the
method of choice for the sEV preparation out of such
liquids. Similarly, although PEG-prepared samples can
be used for molecular analyses, other low-scale meth-
ods being able to enrich EVs to higher purities might
be preferred for down-stream molecular analysis. In
this context, we and others have demonstrated that
the combination of different methods or immunecap-
turing technologies allow the separation of sEVs from
other components frequently co-purified with sEVs
and provide several surprises, e.g. that several
miRNAs considered to be EV-associated are eluted in
other fractions than exosomal marker proteins [61–64].
Regarding the reproducibility of the optimised
PEG protocol, we learned that the results obtained
with the PEG protocol were much more reproducible
than those obtained with the conventional differen-
tial centrifugation (DC) protocol. Following UC in
the DC protocol, EV pellets appeared very fragile
and immediately resolved partially in the supernatant
if they were not handled very carefully. To avoid the
Figure 6. Detection of residual PEG. Two gels were loaded with
PEG 6000 in decreasing amounts (10, 5, 2.5, 1, 0.5, 0.25, 0.1,
0.01 µg), protein marker, and 6 µg of the final EV samples of
HEK293T-CD63-eGF clone B2 and C5 cells. Gels were run under
identical conditions. PEG was detectable after barium iodide
staining (a); proteins following protein specific imperial stain
(b). Signals in (a) were recorded with Image Studio™ Software
(LI-COR) and plotted against the PEG concentration of the
calibration values (c). The graphic evolution indicates a linear
equation of y = 15.692× + 3.4984 which was used to calculate
the revealed PEG concentration of 0.02% in the final EV samples.
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EV loss, some residual supernatant is commonly left
on the pellet. Especially, non-trained experimenters
tend to leave higher volumes of supernatants on the
pellets than trained ones. Since supernatants have
very high protein contents, residual amounts of the
supernatant significantly affect the purity of obtained
sEV samples, even after a washing step. Maybe by
means of some residual PEG, the UC pellet following
PEG precipitation is much more solid and was found
to hardly get lost even if non-trained experimenters
performed the PEG precipitation. Remaining super-
natant could easily be rinsed off without affecting the
integrity of these UC pellets. Although intensive
training helped to increase the purity of DC-pre-
pared sEV samples over time, even best trained
experimenters hardly reached the same purity with
the DC method than with the optimised PEG proto-
col. BSA contaminations were always detected in
final DC sEV samples but hardly in any of the final
PEG sEV samples (Figures 4(e) and 5(d)). Thus,
purer sEV samples can be obtained with the opti-
mised PEG method compared to the conventional
DC method.
Several companies provide polymer-based EV pre-
cipitation reagents, commonly also based on PEG.
Regularly, washing procedures of resulting pellets
are not part of the proposed protocols. As demon-
strated in Suppl. Figure 2, PEG pellets prepared with
our method contain detectable levels of BSA before
ultracentrifugation. Following ultracentrifugation, the
BSA is mainly recovered in the supernatant but not
in the final sEV fraction. Although we have not
tested any of the commercial EV precipitation poly-
mers in the present investigation, we like to predict
that a washing procedure will also help to increase
the purity of these samples. Similar to our results,
Rider and colleagues demonstrated that following
PEG precipitation ultracentrifugation increased the
purity of the obtained EV samples [59].
Upon comparing sEV samples prepared by PEG
precipitation with EV samples prepared by sucrose
density gradient centrifugation or size exclusion
chromatography, respectively, we learned that
higher purities – as indicated as particle numbers
measured by NTA per mg protein within the EV
fraction – are obtained with the latter methods.
However, in our hands, the recovery rates were
not very high and sucrose gradient purified EVs
did not get incorporated into target cells.
Apparently, sucrose density gradient centrifugation
affects the physiological properties of the prepared
EVs. Thus, although the PEG method may not pur-
ify EVs to the highest level, EVs apparently retain
their physiological activity. Furthermore, the
method is scalable, for example, for our pre-clinical
studies we had purified with the optimised protocol
up to 10 L MSC-conditioned media within 2 days.
Thus, for the first time, the PEG precipitation
method provided the chance to process volumes
required to obtain enough EVs for the clinical set-
ting [14]. Although, we and others currently focus
on closed systems to prepare EVs for the clinical
setting, such as tangential flow filtration eventually
in combination with other methods [61,65,66],
according to their confirmed therapeutic effects,
PEG-prepared EVs will for the moment serve as
reference regarding purity and activity.
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